rs200696740
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2
The NM_000307.5(POU3F4):c.506C>T(p.Pro169Leu) variant causes a missense change. The variant allele was found at a frequency of 0.000148 in 1,206,558 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 44 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. 11/18 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000307.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
POU3F4 | NM_000307.5 | c.506C>T | p.Pro169Leu | missense_variant | 1/1 | ENST00000644024.2 | NP_000298.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
POU3F4 | ENST00000644024.2 | c.506C>T | p.Pro169Leu | missense_variant | 1/1 | NM_000307.5 | ENSP00000495996.1 | |||
ENSG00000279437 | ENST00000625081.1 | n.385G>A | non_coding_transcript_exon_variant | 1/1 | 6 |
Frequencies
GnomAD3 genomes AF: 0.000133 AC: 15AN: 112563Hom.: 0 Cov.: 24 AF XY: 0.000115 AC XY: 4AN XY: 34711
GnomAD3 exomes AF: 0.000322 AC: 54AN: 167897Hom.: 0 AF XY: 0.000272 AC XY: 15AN XY: 55129
GnomAD4 exome AF: 0.000149 AC: 163AN: 1093995Hom.: 0 Cov.: 31 AF XY: 0.000111 AC XY: 40AN XY: 359899
GnomAD4 genome AF: 0.000133 AC: 15AN: 112563Hom.: 0 Cov.: 24 AF XY: 0.000115 AC XY: 4AN XY: 34711
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Sep 12, 2014 | The Pro169Leu variant in POU3F4 has been identified by our laboratory in one mal e individual with hearing loss (LMM-unpublished data), but was absent from large population studies. Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, the clinical significance of the Pro169Leu variant is uncertain. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 28, 2022 | The c.506C>T (p.P169L) alteration is located in exon 1 (coding exon 1) of the POU3F4 gene. This alteration results from a C to T substitution at nucleotide position 506, causing the proline (P) at amino acid position 169 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
not provided Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 14, 2023 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at